Literature DB >> 6212162

An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus.

A Matsumori, C Kawai.   

Abstract

To investigate whether lesions that develop in the chronic stage of viral myocarditis are similar to those seen in congestive (dilated) cardiomyopathy, we studied myocarditis in inbred strains of DBA/2 mice infected with encephalomyocarditis (EMC) virus. Myocardial necrosis with calcification appeared on day 4. Thereafter, myocardial necrosis became more extensive and mononuclear cell infiltration was evident and was most marked on day 14. On day 90, cellular infiltration had decreased and myocardial fibrosis was prominent. At this stage, the heart weight was significantly greater in the infected mice than in the controls (0.190 +/- 0.028 g vs 0.122 +/- 0.013 g, mean +/- SD) (p less than 0.001) and the cavity dimensions of the left ventricle were larger (1.67 +/- 0.29 mm vs 1.11 +/- 0.20 mm) (p less than 0.001). The diameters of myocardial fibers of the right ventricle, the interventricular septum and the left ventricle were significantly larger than those of the controls (right ventricle, 16.6 +/- 1.8 vs 13.4 +/- 1.5 micrometer; interventricular septum, 17.8 +/- 1.5 vs 13.8 +/- 1.5 micrometer; left ventricle, 19.4 +/- 1.7 vs 14.8 +/- 1.1 micrometer) (p less than 0.001). This study demonstrates that in viral myocarditis in the chronic stage, lesions develop that resemble those seen in congestive cardiomyopathy.

Entities:  

Mesh:

Year:  1982        PMID: 6212162     DOI: 10.1161/01.cir.66.2.355

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review.

Authors:  A D'Ambrosio; G Patti; A Manzoli; G Sinagra; A Di Lenarda; F Silvestri; G Di Sciascio
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

Review 2.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  The arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy.

Authors:  G Fontaine; F Fontaliran; F R Andrade; E Velasquez; J Tonet; X Jouven; Y Fujioka; R Frank
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

4.  Natural history of left ventricular function in neonatal Coxsackie myocarditis.

Authors:  A Rozkovec; G Cambridge; M King; K A Hallidie-Smith
Journal:  Pediatr Cardiol       Date:  1985       Impact factor: 1.655

Review 5.  Approaches to prevention and early detection of cardiomyopathies: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

Review 6.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

7.  Cetirizine a histamine H1 receptor antagonist improves viral myocarditis.

Authors:  Akira Matsumori; Kanjo Yamamoto; Miho Shimada
Journal:  J Inflamm (Lond)       Date:  2010-08-04       Impact factor: 4.981

8.  Cardiac disease in transgenic mice expressing human immunodeficiency virus-1 nef in cells of the immune system.

Authors:  Denis G Kay; Ping Yue; Zaher Hanna; Serge Jothy; Etienne Tremblay; Paul Jolicoeur
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

Authors:  S Matsui; A Matsumori; Y Matoba; A Uchida; S Sasayama
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.